

PATRONAGES - UNDER THE AUSPICES OF:



WITH THE UNCONDITIONED SUPPORT OF:

PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



SCIENTIFIC PROVIDER AND
CONGRESS ORGANIZER

Events srl

Via L. Lotto 9, 60019 Senigallia (AN)
Ph. +39 071 7930220 Fax. +39 071 9252094
www.events-communication.com
segreteria@events-communication.com



5th Edition

LUNG CANCER COCKTAIL WITH SCIENCE 2024

SEPTEMBER 27th - MILAN, ITALY
& ONLINE


SCIENTIFIC PROGRAM

- 10:30** Registration
- 11:00** Welcome and introduction
Giuseppe Lo Russo
Gustavo Galmozzi *President Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Carlo Nicora *General Director Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Filippo de Braud *Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Bruno Aratri *President IPOP Onlus*
- 13:00** LUNCH
- 2 SESSION**
NSCLC NON ONCOGENE ADDICTED ADVANCED DISEASE
Chairs: **M. Brambilla, M. Macerelli, M. Occhipinti**
- 14:00** New biomarkers for patients treated with ICIs
Paolo Bironzo
- 14:20** IO monotherapy; IO-Chemo; IO-IO + Chemo as first line: how to orient yourself?
Marina Chiara Garassino
- 14:40** Duration of IO treatment and IO re-Challenge
Helena Linardou
- 15:00** IO resistance: new approaches
Martin Reck
- 15:20** Round Table and & Questions time
All
- 15:50** COFFEE BREAK
- 3 SESSION**
NSCLC ONCOGENE ADDICTED ADVANCED DISEASE
Chairs: **R. Loporati, C. Proto, G. Viscardi**
- 16:00** New perspectives for liquid biopsy in NSCLC
Umberto Malapelle
- 10:30** Registration
- 11:00** Welcome and introduction
Giuseppe Lo Russo
Gustavo Galmozzi *President Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Carlo Nicora *General Director Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Filippo de Braud *Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*
Bruno Aratri *President IPOP Onlus*

- 16:20** EGFR common and uncommon mutations
Luis Paz Ares
- 16:40** Updates for BRAF, MET, HER2 and KRAS positive patients
Eriqueta Felip Font
- 17:00** Updates for ALK, ROS1, RET, NTRK and NGR1 positive patients
Shirish Gadgeeel
- 17:20** Round Table and & Questions time
All

SPECIAL LECTURES

- Chairs: **T. Beninato, G. Galli, D. Signorelli**
- 17:50** Myeloid cell heterogeneity in lung cancer: implication for immunotherapy
Sabina Sangaletti
- 18:10** SCLC the present and the future
Stephen V Liu
- 18:30** Radon and cancer: current trends and perspectives
Laura Mezquita
- 18:50** Conclusions remarks
Giuseppe Lo Russo
- 19:00** COCKTAIL



OVERVIEW

The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment.

PRESIDENT OF THE CONFERENCE

GIUSEPPE LO RUSSO
Thoracic Unit - Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

GENERAL INFORMATION

- REGISTRATION**
Registration is free of charge.
You may register for IN-PERSON OR ONLINE-ONLY ACCESS
<https://www.events-communication.com/event/lungcancer2024/>
- CONGRESS VENUE**
Grand Visconti Palace
Viale Isonzo, 14 - 20135 Milano
- VIRTUAL CONFERENCE**
<https://www.events-fad.com/>
- OFFICIAL LANGUAGE AND TIME**
The official language is English
The official Time is Central European Summer Time (CEST), UTC +2
- C.M.E. CREDITS**
CME accreditation (valid for Italian participants only) for: Medical Doctor, Chemist, Pharmacist, Biologist, Physician, Nurse.
CME credits RES: 7 - CME credits FAD: 10,5
Italian CME credits will be granted to those participants who attend at least 90% of scienti c works, ll in the questionnaire assessment of perceived quality and duly ll in the evaluation questionnaires answering correctly 75% of the questions.

FACULTY

- Teresa Beninato** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Paolo Bironzo** Oncology Department AOU San Luigi, University of Turin, Torino IT
- Marta Brambilla** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Tina Cascone** Dpt. Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA
- Filippo De Braud** Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Ferrara Roberto** Thoracic Oncology and Molecular Immunology IRCCS Ospedale San Raffaele, Milano IT
- Enriqueta Felip Font** Lung Cancer Unit, Oncology Department Vall d'Hebron University Hospital Barcelona, ES
- Andrea Riccardo Filippi** Radiation Oncology University of Milan, Radiotherapy, Istituto Nazionale Tumori, Milano IT
- Shirish Gadgeeel** Division of Hematology and Oncology, Dpt. of Internal Medicine, Henry Ford Cancer Institute, Detroit, MI USA
- Giulia Galli** Medical Oncology Fondazione IRCCS Policlinico San Matteo, Pavia IT
- Marina Chiara Garassino** Thoracic Oncology Program, University of Chicago, IL USA
- Rita Loporati** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Helena Linardou** Oncology Dpt. and Comprehensive Clinical Trials Center of Metropolitan Hospital, Athens, GR
- Giuseppe Lo Russo** Thoracic Unit - Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Stephen V Liu** Medical Oncology, Thoracic Oncology, Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, Washington, DC USA
- Marianna Macerelli** Medical Oncology Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Udine IT
- Umberto Malapelle** Department of Public Health, University Federico II of Naples, Napoli IT
- Laura Mezquita** Medical Oncology Hospital Clinic Barcelona, Barcelona ES
- Laura Mazzeo** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Mario Occhipinti** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Ugo Pastorino** Dpt. of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Luis Paz Ares** Medical Oncology Dpt. Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Lung Cancer Unit National Oncology Research Center, Madrid ES
- Arsela Prelaj** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Claudia Proto** Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Martin Reck** Dpt. of Thoracic Oncology, Lung Clinic Grosshansdorf, DE
- Jordi Remon Masip** Dpt. of Cancer Medicine, Gustave Roussy, Villejuif, FR
- Sabina Sangaletti** Tumor Genomics Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT
- Diego Signorelli** Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano IT
- Viscardi Giuseppe** Medical Oncology, AO Monaldi Cotugno Cto, Università degli Studi della Campania Luigi Vanvitelli, Napoli IT